Skip to main content
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · TARS ISIN · US87650L1035 US Manufacturing
Open in API
Filings indexed 576 across all filing types
Latest filing 2021-11-03 Regulatory Filings
Country US United States of America
Listing US TARS

About Tarsus Pharmaceuticals, Inc.

https://www.tarsusrx.com/

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for diseases with limited treatment options. The company's initial focus is on eye care. Its lead product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is the first and only FDA-approved treatment for Demodex blepharitis. Tarsus is also advancing a pipeline of potential treatments for other conditions with high unmet needs, including ocular rosacea, Lyme disease prevention, and other indications across dermatology and infectious diseases.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings
2021-11-03 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 1, 2021. It announces the filing of a Shelf Registration Statement on Form S-3 for up to $300 million in securities and a Sale Agreement prospectus for up to $100 million of common stock. The document primarily provides an update on the company's capital raising activities and related agreements. There are no financial statements or detailed financial results included, nor is it an annual or quarterly report. The content focuses on financing activities and capital structure updates. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is 4383 characters, which is sufficient to provide substantive information rather than a mere announcement. Hence, the classification is CAP with high confidence.
2021-11-01 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Tarsus Pharmaceuticals, Inc. It is a registration statement under the Securities Act of 1933 for the offering of securities including common stock, preferred stock, debt securities, warrants, and units. The document includes a base prospectus and a sales agreement prospectus, describing the terms and conditions for securities offerings up to $300 million. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to capital raising activities but is not an update or announcement of financing activity per se. The document is lengthy (15,000 characters) and contains detailed registration and offering information. This type of filing is best classified as a Capital/Financing Update (CAP) because it relates to the registration and offering of securities for capital raising purposes under SEC rules.
2021-11-01 English
FORM 4
Director's Dealing
2021-10-14 English
FORM 4
Director's Dealing
2021-10-14 English
FORM 4
Director's Dealing
2021-10-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.